INTERCEPT PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Intercept Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q3 2023.
  • Intercept Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$4.62M, a 54.5% increase year-over-year.
  • Intercept Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$62.3M, a 21.3% increase year-over-year.
  • Intercept Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$68.2M, a 32.1% increase from 2021.
  • Intercept Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$100M, a 56.3% increase from 2020.
  • Intercept Pharmaceuticals, Inc. annual Operating Income (Loss) for 2020 was -$230M, a 26.5% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$62.3M -$4.62M +$5.53M +54.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 -$67.8M -$7.12M +$6.24M +46.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 -$74M -$31.6M -$5.2M -19.7% Jan 1, 2023 Mar 31, 2023 10-Q 2023-04-27
Q4 2022 -$68.8M -$18.9M +$10.3M +35.2% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-02
Q3 2022 -$79.1M -$10.1M +$9.34M +47.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$88.5M -$13.4M -$210K -1.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$88.2M -$26.4M +$12.2M +31.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-27
Q4 2021 -$100M -$29.2M +$11.4M +28.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$112M -$19.5M +$35.7M +64.7% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-02
Q2 2021 -$148M -$13.2M +$38.9M +74.7% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-02
Q1 2021 -$186M -$38.6M +$44.9M +53.7% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-02
Q4 2020 -$231M -$40.6M +$48.7M +54.5% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$280M -$55.2M +$20.4M +27% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$300M -$52M +$11.6M +18.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$312M -$83.4M +$500K +0.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$312M -$89.3M -$7.32M -8.93% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$305M -$75.5M -$17.2M -29.6% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$288M -$63.7M +$6.12M +8.77% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$294M -$83.9M -$8.49M -11.3% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$285M -$82M +$23M +21.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-25
Q3 2018 -$308M -$58.3M +$7.89M +11.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-25
Q2 2018 -$316M -$69.8M +$10.7M +13.3% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-25
Q1 2018 -$327M -$75.5M +$8.51M +10.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-25
Q4 2017 -$336M -$105M +$9.04M +7.93% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 -$345M -$66.2M +$16.9M +20.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 -$362M -$80.5M -$2.41M -3.09% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 -$359M -$84M +$43.4M +34.1% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 -$403M -$114M -$25.1M -28.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-28
Q3 2016 -$377M -$83M -$31.3M -60.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-28
Q2 2016 -$346M -$78.1M -$29.3M -60% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-28
Q1 2016 -$317M -$127M -$87.7M -221% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-28
Q4 2015 -$229M -$88.9M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$51.8M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$48.8M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 -$39.7M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.